Pharmacy Medical News about Neuralgia Pain Cannabinoids

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside
Neurotherapeutics, 10/05/09

Rahn EJ et al. – In humans, effects of smoked marijuana, synthetic delta9–THC analogs (e.g., Marinol, Cesamet) and medicinal cannabis preparations containing both delta9–THC and cannabidiol (e.g., Sativex, Cannador) in neuropathic pain states are reviewed. Clinical studies largely affirm that neuropathic pain patients derive benefits from cannabinoid treatment. Subjective (i.e., rating scales) and objective (i.e., stimulus–evoked) measures of pain and quality of life are considered. Finally, limitations of cannabinoid pharmacotherapies are discussed together with directions for future research.

<< Previous
A review of drug-induced hypocalcemia

Next >>
Acyclovir Susceptibility and Genetic Characteristics of...